Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cytek BiosciencesCTKB +0.44%71 3-Year Share Buyback Ratio is 1.70 as of Mar. 2026, which is 209% above its 10-year median of 0.55. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.83 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 615 Medical Devices & Instruments companies, Cytek Biosciences ranks better than 94.31% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Cytek Biosciences's current 3-Year Share Buyback Ratio was 1.70%.
The historical rank and industry rank for Cytek Biosciences's 3-Year Share Buyback Ratio or its related term are showing as below:
CTKB'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -1.1 Med: 0.55 Max: 1.7
Current: 1.7
During the past 7 years, Cytek Biosciences's highest 3-Year Share Buyback Ratio was 1.70%. The lowest was -1.10%. And the median was 0.55%.
CTKB's 3-Year Share Buyback Ratio is ranked better than 94.31% of 615
companies
in the Medical Devices & Instruments industry
Industry Median: -2.7
vs CTKB: 1.70
Cytek Biosciences (NAS:CTKB) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Cytek Biosciences 3-Year Share Buyback Ratio Related Terms
CTKB vs CERS, NPCE, CLPT: 3-Year Share Buyback Ratio Comparison
For the Medical Devices subindustry, Cytek Biosciences's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences 3-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's 3-Year Share Buyback Ratio falls into.
Cytek Biosciences 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 1.70 mean?
Cytek Biosciences (CTKB) has a 3-Year Share Buyback Ratio of 1.70 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Cytek Biosciences and its competitors. This is 209% above median its historical median of 0.55. According to the industry distribution chart, Cytek Biosciences ranks #35 out of 615 companies in the Medical Devices & Instruments industry, placing it in the top 5.7%.
Is Cytek Biosciences' 3-Year Share Buyback Ratio too high?
Cytek Biosciences' current 3-Year Share Buyback Ratio of 1.70 is 209% above median its 10-year median of 0.55. Based on the distribution chart, Cytek Biosciences ranks #35 out of 615 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' 3-Year Share Buyback Ratio compare to CERS and NPCE?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #35 out of 615 companies for 3-Year Share Buyback Ratio. This places Cytek Biosciences in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Cytek Biosciences and its competitors. Cytek Biosciences's current 3-Year Share Buyback Ratio is 1.70, which is 209% above median its own 10-year median of 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.83, compared to a current price of $4.56 — trading 21.8% below its estimated fair value. The current 3-Year Share Buyback Ratio is 1.70, which is 209% above median its 10-year median of 0.55. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current 3-Year Share Buyback Ratio is 1.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.56 is trading 21.8% below its estimated GF Value™ of $5.83.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
3-Year Share Buyback Ratio: 1.70 (209% above median its 10-year median of 0.55)
GF Value™: $5.83 vs. price of $4.56 (21.8% below fair value)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score
Get the complete analysis for CTKB
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
